ResMed Inc.
NYSE:RMDMedical - Devices
+$1.58 today
- Market cap
- $34.12B
- Beta
- 0.78
- P/E (TTM)
- 18.1
- EPS (TTM)
- $10.37
- Dividend yield
- 1.28%
Volume 1.22M
Average 1.32M
RMD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
ResMed Inc.NYSE: RMD
EBITDA · Q4 FY2026 · quarter ended Jun 2026
EBITDA dips below year-ago levels
Q4 FY2026 EBITDA of $503.83M fell 5.4% year over year, behind the +12.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 13.7% from the prior quarter. Over 3 fiscal years it compounded at +16.5% a year.
Context
- EBITDA amounted to 38.1% of revenue in FY2026, up 0.9 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 22 analysts of $2.42B (+12.3%) for the fiscal year ending Jun 2027, a pace similar to FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $503.83M-13.7% QoQ
- Last fiscal yearJun 2026
- $2.15B+12.5% YoY
- LTMJun 2026
- $2.17B+12.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.4% | +1.5% | +6.8 pp |
| 1 year | +12.5% | +12.3% | -0.2 pp |
| 3-year CAGR | +16.5% | +7.3% | -9.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2026
- 2.15B USD
- Year-over-year change
- +12.5%
- 4-year CAGR
- +16.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 2.15B | +12.5% |
| FY2025 | 2025-06-30 | 1.91B | +24.8% |
| FY2024 | 2024-06-30 | 1.53B | +12.8% |
| FY2023 | 2023-06-30 | 1.36B | +15.6% |
| FY2022 | 2022-06-30 | 1.18B | — |
EBITDA vs competitors
How RMD compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.7% is the 4th highest of 9, against a peer median of +10.8%.
- EBITDA amounts to 38.3% of revenue for RMD, versus a peer median of 18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $10.27B USD | +9.8% | +4.1% | 27.3% | |
| LTM Jun 2026 | $5.8B USD | +23.2% | +23.0% | 27.6% | |
| LTM Sep 2026 | $4.19B USD | +11.9% | +26.5% | 36.2% | |
| LTM Jun 2026 | $3.07B USD | -19.7% | +6.1% | 15.2% | |
| LTM Jun 2026 | €3.05B EUR | +62.1% | +184.2% | 17.3% | |
| LTM Jun 2026 | $2.17B USD | +12.7% | +16.5% | 38.3% | |
| LTM Jun 2026 | $83.09M USD | -4.7% | — | 9.2% | |
| LTM Mar 2026 | $14.78M USD | +39.5% | +46.7% | 20.6% | |
| LTM Jun 2026 | -$158.49M USD | -126.4% | -25.5% | 6.1% | |
| Peer median (excluding RMD) | — | +10.8% | +23.0% | 18.9% | |
Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 3.58B | 4.22B | 4.69B | 5.15B | 5.65B |
| Cost of Revenue | 1.55B | 1.87B | 2.03B | 2.09B | 2.2B |
| Gross Profit | 2.02B | 2.36B | 2.66B | 3.05B | 3.45B |
| Gross Margin | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% |
| Research & Development | 253.58M | 287.64M | 307.53M | 331.28M | 378.29M |
| Selling, General & Admin | 739.37M | 874M | 917.14M | 991.02M | 1.12B |
| Operating Expenses | 1.02B | 1.22B | 1.34B | 1.37B | 1.54B |
| Depreciation & Amortization | 193.84M | 197.56M | 216.21M | 235.81M | 244.15M |
| EBITDA | 1.18B | 1.36B | 1.53B | 1.91B | 2.15B |
| EBITDA Margin | 32.9% | 32.2% | 32.7% | 37.2% | 38.1% |
| Operating Income | 1B | 1.13B | 1.32B | 1.69B | 1.91B |
| Operating Margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.31M | 47.38M | 45.71M | 12.61M | 0 |
| Other Income / Expenses | (39.8M) | (30.21M) | (55.1M) | (7.8M) | 10.96M |
| Income Before Tax | 960.48M | 1.1B | 1.26B | 1.68B | 1.92B |
| Pre-Tax Margin | 26.8% | 26.1% | 27.0% | 32.6% | 34.0% |
| Income Tax Expense | 181.05M | 204.11M | 243.85M | 276.84M | 396.12M |
| Net Income | 779.44M | 897.56M | 1.02B | 1.4B | 1.52B |
| Net Margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| EPS (Basic) | 5.34 | 6.12 | 6.94 | 9.55 | 10.44 |
| EPS (Diluted) | 5.30 | 6.09 | 6.92 | 9.51 | 10.40 |
| Weighted Avg Shares | 146.07M | 146.77M | 147.02M | 146.72M | 144.71M |
| Weighted Avg Shares (Diluted) | 147.04M | 147.46M | 147.55M | 147.34M | 144.98M |
ResMed Inc.
NYSE:RMD
Intrinsic Alpha fair value
Locked
Current Price
$242.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.